2. Search Result
Search Result
Pathways Recommended: Membrane Transporter/Ion Channel
Results for "

RAS membrane localization

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16111
    BMS-214662

    		Farnesyl Transferase Ras Cancer
    BMS-214662 is a farnesyl transferase inhibitor. BMS-214662 can effectively block the localization and function of Ras protein in the cell membrane by inhibiting the pro-group modification of Ras protein, thereby exerting anti-tumor activity. BMS-214662 has an IC50 value of 1.3 nM for H-Ras and 8.4 nM for K-Ras. BMS-214662 can be used to study Ras-related tumor diseases .
    BMS-214662
  • HY-16111A
    BMS-214662 hydrochloride

    		Farnesyl Transferase Ras Cancer
    BMS-214662 hydrochloride is an inhibitor of farnesyltransferase (Farnesyl Transferase). BMS-214662 hydrochloride can effectively block the localization and function of Ras proteins on the cell membrane by inhibiting the prenylation modification of Ras proteins, thereby exerting anti-tumor activity. The IC50 value of BMS-214662 hydrochloride for H-Ras is 1.3 nM, and for K-Ras it is 8.4 nM. BMS-214662 hydrochloride can be used in the research of tumor diseases related to Ras .
    BMS-214662 hydrochloride
  • HY-B0984A
    Fendiline
    2 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline
  • HY-B0984
    Fendiline hydrochloride
    2 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride
  • HY-128350A
    FGTI-2734 mesylate
    1 Publications Verification

    		 Farnesyl Transferase γ-Glutamyl Transferase (GGT) Cancer
    FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors .
    FGTI-2734 mesylate
  • HY-128350
    FGTI-2734
    1 Publications Verification

    		 Farnesyl Transferase Cancer
    FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors .
    FGTI-2734
  • HY-149709
    ICMT-IN-35

    		ICMT Cancer
    ICMT-IN-35 (compound 10n) is a FTPA-triazole compound and ICMT inhibitor (IC50=0.8 μM). ICMT-IN-35 is taken up by mammalian cells and can prevent K-Ras membrane localization and induce K-Ras mislocalization. Furthermore, ICMT-IN-35 is selectively cytotoxic against ICMT +/+ MEF cells and has low micromolar activity (IC50=0.8 μM) against metastatic pancreatic cancer cell lines .
    ICMT-IN-35
  • HY-B0984R
    Fendiline hydrochloride (Standard)

    		Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride (Standard)
  • HY-155422
    ICMT-IN-13

    		ICMT Cancer
    ICMT-IN-13 (compound 49) is an inhibitor of ICMT (IC50=0.47 μM) .
    ICMT-IN-13
  • HY-157114
    ICMT-IN-46

    		ICMT Cancer
    ICMT-IN-46 (compound 25) is an inhibitor of ICMT (IC50=0.556 μM) .
    ICMT-IN-46
  • HY-157100
    ICMT-IN-23

    		ICMT Cancer
    ICMT-IN-23 (compound 36) is an inhibitor of ICMT (IC50=0.123 μM) .
    ICMT-IN-23
  • HY-149706
    ICMT-IN-12

    		ICMT Cancer
    ICMT-IN-12 (compound 78) is an inhibitor of ICMT (IC50=0.42 μM) .
    ICMT-IN-12
  • HY-157096
    ICMT-IN-8

    		ICMT Cancer
    ICMT-IN-8 (compound 30) is an inhibitor of ICMT (IC50=0.652 μM) .
    ICMT-IN-8
  • HY-156500
    ICMT-IN-1

    		ICMT Cancer
    ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC50=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
    ICMT-IN-1
  • HY-155433
    ICMT-IN-30

    		ICMT Cancer
    ICMT-IN-30 (compound 67) is an inhibitor of ICMT (IC50=0.27 μM) .
    ICMT-IN-30
  • HY-157092A
    (S)-ICMT-IN-3

    		ICMT Cancer
    (S)-ICMT-IN-3 (compound ent 1-27) is an inhibitor of ICMT (IC50=0.23 μM) .
    (S)-ICMT-IN-3
  • HY-155431
    ICMT-IN-28

    		ICMT Cancer
    ICMT-IN-28 (compound 65) is an inhibitor of ICMT (IC50=0.008 μM) .
    ICMT-IN-28
  • HY-157120
    ICMT-IN-52

    		ICMT Cancer
    ICMT-IN-52 (compound 44) is an inhibitor of ICMT (IC50=0.052 μM) .
    ICMT-IN-52
  • HY-155419
    ICMT-IN-5

    		ICMT Cancer
    ICMT-IN-5 (compound 46) is an inhibitor of ICMT (IC50=0.3 μM) .
    ICMT-IN-5
  • HY-157103
    ICMT-IN-34

    		ICMT Cancer
    ICMT-IN-34 (compound 39) is an inhibitor of ICMT (IC50=0.17 μM) .
    ICMT-IN-34
  • HY-157119
    ICMT-IN-51

    		ICMT Cancer
    ICMT-IN-51 (compound 43) is an inhibitor of ICMT (IC50=0.55 μM) .
    ICMT-IN-51
  • HY-149705
    ICMT-IN-7

    		ICMT Cancer
    ICMT-IN-7 (compound 74) is an inhibitor of ICMT (IC50=0.015 μM). ICMT-IN-7 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
    ICMT-IN-7
  • HY-157095
    ICMT-IN-6

    		ICMT Cancer
    ICMT-IN-6 (compound 29) is an inhibitor of ICMT (IC50=0.09 μM) .
    ICMT-IN-6
  • HY-157118
    ICMT-IN-50

    		ICMT Cancer
    ICMT-IN-50 (compound 3) is an inhibitor of ICMT (IC50=0.31 μM) .
    ICMT-IN-50
  • HY-155429
    ICMT-IN-24

    		ICMT Cancer
    ICMT-IN-24 (compound 63) is an inhibitor of ICMT (IC50=0.19 μM) .
    ICMT-IN-24
  • HY-155424
    ICMT-IN-15

    		ICMT Cancer
    ICMT-IN-15 (compound 51) is an inhibitor of ICMT (IC50=0.032 μM) .
    ICMT-IN-15
  • HY-157105
    ICMT-IN-37

    		ICMT Cancer
    ICMT-IN-37 (compound 41) is an inhibitor of ICMT (IC50=0.308 μM) .
    ICMT-IN-37
  • HY-155430
    ICMT-IN-27

    		ICMT Cancer
    ICMT-IN-27 (compound 64) is an inhibitor of ICMT (IC50=0.1 μM) .
    ICMT-IN-27
  • HY-155427
    ICMT-IN-20

    		ICMT Cancer
    ICMT-IN-20 (compound 54) is an inhibitor of ICMT (IC50=0.682 μM) .
    ICMT-IN-20
  • HY-157112
    ICMT-IN-44

    		ICMT Cancer
    ICMT-IN-44 (compound 23) is an inhibitor of ICMT (IC50=0.167 μM) .
    ICMT-IN-44
  • HY-157092B
    (R)-ICMT-IN-3

    		ICMT Cancer
    (R)-ICMT-IN-3 (compound ent 2-27) is an inhibitor of ICMT (IC50=0.01 μM) .
    (R)-ICMT-IN-3
  • HY-157104
    ICMT-IN-36

    		ICMT Cancer
    ICMT-IN-36 (compound 40) is an inhibitor of ICMT (IC50=0.181 μM) .
    ICMT-IN-36
  • HY-149707
    ICMT-IN-21

    		ICMT Cancer
    ICMT-IN-21 (compound 6ag) is an ICMT inhibitor (IC50=8.8 μM), a sulfonamide-modified farnesyl cysteine (SMFC). The farnesyl and carboxylic acid motifs of ICMT-IN-21 are important structures for inhibiting ICMT .
    ICMT-IN-21
  • HY-155425
    ICMT-IN-17

    		ICMT Cancer
    ICMT-IN-17 (compound 52) is an inhibitor of ICMT (IC50=0.38 μM) .
    ICMT-IN-17
  • HY-157102
    ICMT-IN-26

    		ICMT Cancer
    ICMT-IN-26 (compound 38) is an inhibitor of ICMT (IC50=0.36 μM) .
    ICMT-IN-26
  • HY-157098
    ICMT-IN-16

    		ICMT Cancer
    ICMT-IN-16 (compound 33) is an inhibitor of ICMT (IC50=0.131 μM) .
    ICMT-IN-16
  • HY-157109
    ICMT-IN-41

    		ICMT Cancer
    ICMT-IN-41 (compound 20) is an inhibitor of ICMT (IC50=0.069 μM) .
    ICMT-IN-41
  • HY-155434
    ICMT-IN-31

    		ICMT Cancer
    ICMT-IN-31 (compound 68) is an inhibitor of ICMT (IC50=0.0038 μM) .
    ICMT-IN-31
  • HY-149730
    ICMT-IN-54

    		ICMT Cancer
    ICMT-IN-54 (compound 7c) is an adamantyl analogue and an ICMT inhibitor (IC50=12.4 μM), which can inhibit ICMT Methylation. ICMT-in-54 inhibits BFC (N-biotinyl-(6-aminohexanoic)-S-farnesyl-L-cysteine) methylation in saccharomyces cerevisiae expressing ICMT, which is an indirect effect of inhibiting ICMT methylation .
    ICMT-IN-54
  • HY-157099
    ICMT-IN-18

    		ICMT Cancer
    ICMT-IN-18 (compound 35) is an inhibitor of ICMT (IC50=0.066 μM) .
    ICMT-IN-18
  • HY-157108
    ICMT-IN-40

    		ICMT Cancer
    ICMT-IN-40 (compound 19) is an inhibitor of ICMT (IC50=0.031 μM) .
    ICMT-IN-40
  • HY-155421
    ICMT-IN-11

    		ICMT Cancer
    ICMT-IN-11 (compound 48) is an inhibitor of ICMT (IC50=0.031 μM) .
    ICMT-IN-11
  • HY-155432
    ICMT-IN-29

    		ICMT Cancer
    ICMT-IN-29 (compound 66) is an inhibitor of ICMT (IC50=0.019 μM) .
    ICMT-IN-29
  • HY-157106
    ICMT-IN-38

    		ICMT Cancer
    ICMT-IN-38 (compound 42) is an inhibitor of ICMT (IC50=0.049 μM) .
    ICMT-IN-38
  • HY-157111
    ICMT-IN-43

    		ICMT Cancer
    ICMT-IN-43 (compound 22) is an inhibitor of ICMT (IC50=0.04 μM) .
    ICMT-IN-43
  • HY-157107
    ICMT-IN-39

    		ICMT Cancer
    ICMT-IN-39 (compound 18) is an inhibitor of ICMT (IC50=0.031 μM) .
    ICMT-IN-39
  • HY-155435
    ICMT-IN-32

    		ICMT Cancer
    ICMT-IN-32 (compound 70) is an inhibitor of ICMT (IC50=0.777 μM) .
    ICMT-IN-32
  • HY-157097
    ICMT-IN-10

    		ICMT Cancer
    ICMT-IN-10 (compound 32) is an inhibitor of ICMT (IC50=0.184 μM) .
    ICMT-IN-10
  • HY-157101
    ICMT-IN-25

    		ICMT Cancer
    ICMT-IN-25 (compound 37) is an inhibitor of ICMT (IC50=0.025 μM) .
    ICMT-IN-25
  • HY-149729
    ICMT-IN-53

    		ICMT Cancer
    ICMT-IN-53 (compound 12) is an ICMT inhibitor (IC50=0.96 μM) with PAMPA permeability and antiproliferative activity. ICMT-IN-53 inhibits the proliferation of MDA-MB-231 and PC3 with IC50s of 5.14 μM and 5.88 μM, respectively .
    ICMT-IN-53

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: